ArticleInternational journal of molecular sciences2020
Determinants of Increased Serum Calprotectin in Patients with Type 2 Diabetes Mellitus.
Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 33 citations in OpenAlex.
- Analysis of Biomarkers in Diabetic Foot Ulcer Patients With Dampness-Heat Syndrome Based on 4D-DIA Proteomics Technology.Journal of diabetes research · 2026Article
- Feasibility and preliminary effects of high-intensity interval training vs. moderate-intensity continuous training on inflammatory and metabolic biomarkers in type 2 diabetes: a pilot randomized controlled trial.Journal of diabetes and metabolic disorders · 2025Article
- Plasma Calprotectin and New-onset Type 2 Diabetes in the General Population: A Prospective Cohort Study.The Journal of clinical endocrinology and metabolism · 2024Article
- Triple threat: how diabetes results in worsened bacterial infections.Infection and immunity · 2024Review
- A novel metric-based approach of scoring early host immune response from oro-nasopharyngeal swabs predicts COVID-19 outcome.Scientific reports · 2024Article
- A Prospective Study of the Association Between Plasma Calprotectin Levels and New-Onset CKD in the General Population.Kidney international reports · 2024Article
- Pilot study to evaluate hypercoagulation and inflammation using rotational thromboelastometry and calprotectin in COVID-19 patients.PloS one · 2023Article
- Emerging New Biomarkers for Cardiovascular Disease.International journal of molecular sciences · 2022Article
- IL-1 Mediates Tissue-Specific Inflammation and Severe Respiratory Failure in COVID-19.Journal of innate immunity · 2022Article
- Assessment of Inflammatory Markers in Children with Cow's Milk Allergy Treated with a Milk-Free Diet.Nutrients · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Circulating calprotectin is a potential biomarker for endovascular inflammation in type 2 diabetes mellitus (T2DM). We investigated the determinants of calprotectin and its relationship with the presence of cardiovascular disease (CVD) in 362 T2DM patients included in the Diabetes and Lifestyle Cohort Twente-1 (DIALECT-1) study. Lifestyle exposures, including nutrition, were determined by validated questionnaires. CVD was defined as coronary artery diseases, strokes, and peripheral artery diseases. Median serum calprotectin levels were 1.04 mg/L [IQR: 0.73-1.46 mg/L] and were higher in women (1.11 mg/L) than men (0.96 mg/L,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.